Recent Updates
Recently added Catalysts
XLO Positive Sentiment

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Wednesday, January 31, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xilio Therapeutics, a clinical-stage biotechnology company, announced that its CEO, René Russo, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The event will focus on tumor-activated immuno-oncology therapies developed by the company for cancer patients. A live webcast of the discussion will be available on their website, along with a replay accessible for 30 days post-event. This participation reflects Xilio's ongoing efforts in innovation and investor transparency.
Price reaction · baseline $9.31 (2024-01-30 close) · hit after-hours · clean, no other XLO news in the window
day 0 close
-2.3%
day 1
+0.8%
day 3
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xilio Therapeutics is actively participating in a major biotechnology conference.
  • The CEO will present their innovative tumor-activated immuno-oncology therapies.
  • The company shows commitment to investor engagement with live webcasts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Investors: Media:
Melissa Forst Dan Budwick
Argot Partners 1AB
Xilio@argotpartners.com dan@1abmedia.com

Frequently Asked Questions

When will René Russo participate in the Guggenheim Conference?

René Russo will participate on February 7, 2024, at 12:30 pm EST.

Where can I watch the live webcast of the conference?

The live webcast can be accessed in the ‘Events & Presentations’ section on the Xilio website.

How long will the webcast replay be available?

The replay of the webcast will be available for 30 days after the presentation.

What is Xilio Therapeutics focused on developing?

Xilio Therapeutics is developing tumor-activated immuno-oncology therapies.

Who should I contact for more information?

Contact Melissa Forst for investors or Dan Budwick for media inquiries.

ShareAdd on Google
Tags: XLO Viatris Investor Conferences Healthcare Xilio Therapeutics immuno-oncology biotechnology René Russo
Last updated: Jan 31, 2024

Biotech snapshot

Cash runway
$136M liquidity · $6M/mo burn
~22 mo
Low dilution risk
Lead asset
XTX501Phase 1
Metastatic NSCLC - Non-Small Cell Lung Cancer →

Catalyst track record

+66%
best trade around XLO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XLO.

See every catalyst's timing & PoA →